MedTrace Logo

Efficacy of Extended Infusion of β-lactam Antibiotics for the Treatment of Febrile Neutropenia in Hematologic Patients

NCT04233996 · Status: UNKNOWN · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 150

Last updated 2021-02-12

No results posted yet for this study

Summary

This study evaluates the administration of beta-lactam antibiotics in extended infusion in hematological patients with febrile neutropenia after 5 days of treatment. The beta-lactam antibiotics analyzed are the following: piperacillin-tazobactam, cefepime and meropenem. Half of patients will receive the antibiotic in intermittent infusion, while the other half will receive it in extended infusion.

Conditions

Interventions

DRUG

Piperacillin-Tazobactam 4 g-0.5 g

Patients with FN who empirical treatment with piperacillin-tazobactam 4g/6h

DRUG

Cefepime 2000 mg

Patients with FN who required empirical treatment with cefepime 2g/8h

DRUG

Meropenem 1000 mg

Patients with FN who required empirical treatment with meropenem 1g/8h

Sponsors & Collaborators

  • Institut d'Investigació Biomèdica de Bellvitge

    collaborator OTHER

  • Instituto de Salud Carlos III

    collaborator OTHER_GOV

  • Hospital Universitari de Bellvitge

    lead OTHER

Principal Investigators

  • Carlota Gudiol, PhD · Hospital Universitari de Bellvitge

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-06-05
Primary Completion
2021-12-30
Completion
2022-12-31

Countries

  • Spain

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04233996 on ClinicalTrials.gov